ClinicalTrials.gg
CompletedNCT02937454Affirm-AHFUpdated Jun 18, 2021Results posted

Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency

A Phase 4 interventional study of ferric carboxymaltose and Normal saline 0.9% in Iron Deficiency and Heart Failure, sponsored by Vifor (International) Inc.. Completed at 16 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-18.

Sponsored by Vifor (International) Inc. (part of CSL Limited) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing ferric carboxymaltose in Iron Deficiencies — 8 open to participants now, 8 under way, 2 of them phase 3. ferric carboxymaltose · Iron Deficiencies.

Enrollment
Largest of 40
1,132 · median 134
Started
2017
with 2 others
Phase 4
18 of 40
6 open now
Registered
22nd of 40
by date

Among the 40 studies testing ferric carboxymaltose in Iron Deficiencies, this one has the largest enrollment, is one of 3 that started in 2017, is one of 18 in phase 4, and was the 22nd registered.

Iron Deficiencies

386 studies on the registry are indexed under Iron Deficiencies; 80 are open to participants now.

Browse Iron Deficiencies studies →

Open to participants now

8 of the 40 studies testing ferric carboxymaltose in Iron Deficiencies are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Iron Deficiencies studies recruiting now, 23 (42%) set no upper age limit and 28 (51%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing ferric carboxymaltose in Iron Deficiencies, or all of them as a file.
02

Study summary

Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency (Affirm-AHF)

Read the detailed description

This is a randomised, double-blind, placebo-controlled Trial (RCT). The 52 weeks observation period following randomisation is considered appropriate to investigate the primary endpoint of recurrent HF hospitalisations and CV death. To evaluate the effect of intravenous ferric carboxymaltose (IV FCM) in iron deficient subjects with AHF, subjects will be enrolled during a hospital stay (Index hospitalisation) after the acute care treatment of the index event has been stabilised. All subjects will continue to receive their established standard therapy for HF and medical emergencies will be treated according to local routine.

03

Conditions studied

  • Iron Deficiency
  • Heart Failure

Keywords

  • Acute Heart Failure
  • Iron Deficiency
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Currently hospitalised for an episode of acute heart failure (AHF) where AHF was the primary reason for hospitalisation. All of the following (i.e., items a to d) must apply:

    1. Upon admission for the AHF episode, persistent dyspnoea at rest in a recumbent sitting position (30-45°) or with minimal exertion
    2. Upon or during the AHF admission, at least 2 of the following clinical findings were present: i. Congestion on chest X-ray ii. Rales on chest auscultation iii. Oedema ≥1+ on a 0-3+ scale, indicating indentation of skin with mild digital pressure that requires 10 or more seconds to resolve in any dependent area including extremities or sacral region iv. Elevated jugular venous pressure (≥8 cm H2O)
    3. Natriuretic peptide levels, measured ≤72 hours of the AHF admission must have been: i. Brain natriuretic peptide (BNP) ≥400 pg/mL or N-terminal-pro-brain natriuretic peptide (NT-proBNP) ≥1,600 pg/mL or ii. BNP ≥600 pg/mL or NT-proBNP ≥2,400 pg/mL for subjects presenting with atrial fibrillation when the blood sample was taken iii. For subjects treated with an angiotensin receptor neprilysin inhibitor (ARNI) in the previous 4 weeks prior to randomisation only NT-proBNP values should be considered
    4. AHF episode treated with minimally 40 mg of IV furosemide (or equivalent IV loop diuretic defined as 20 mg of torasemide or 1 mg of bumetanide)
  2. Subject is iron deficient defined as serum ferritin \<100 ng/mL or 100 ng/mL ≤ serum ferritin ≤299 ng/mL if TSAT \<20%.
  3. \<50% (assessed and documented within 12 months prior to randomisation).
  4. Male or female aged ≥18 years old.
  5. Subject (or legally acceptable representative)* has provided the appropriate written . Subject must provide written informed consent before any study-specific procedures are performed.

Exclusion criteria

Exclusion Criteria:

  1. Dyspnoea due to non-cardiac causes such as acute or chronic respiratory disorders or infections (i.e., severe , acute bronchitis, pneumonia, primary pulmonary hypertension).
  2. Temperature >38°C (oral or equivalent), active infective endocarditis, sepsis, systemic inflammatory response syndrome, or any other active infection requiring anti-microbial treatment at any time during an Index hospitalisation. (Note that it does NOT include short-term prophylactic administration of antibiotics or short-term temperature elevation at admission which is no longer present at the time point of discharge/randomisation).
  3. Documented restricted amyloid myocardiopathy, or acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy. (Note that it does NOT include restrictive mitral filling patterns seen on Doppler echocardiographic assessments of diastolic function).
  4. Clinical evidence of acute coronary syndrome, or stroke, within the last 30 days prior randomisation.
  5. Severe valvular or left ventricular outflow obstruction disease needing intervention.
  6. Coronary-artery bypass graft, cardiac resynchronisation therapy device implantation, percutaneous intervention (e.g., cardiac, cerebrovascular, aortic, diagnostic catheters are allowed) or major surgery that led to significant blood loss, including thoracic and cardiac surgery, within the last 3 months prior to randomisation.
  7. Subject has a body weight \<35 kg at randomisation.
  8. Subject at an immediate need of transfusion or with a \<8 g/dL* or with a Hb >15 g/dL.
  9. Subjects on treatment for Vitamin B12 and/or serum folate deficiency. Note: Use of Vitamin B12 and folic acid as supplement therapy (not for deficiency treatment) is permitted.
  10. Subject with a known anaemia not attributed to ID (e.g., other microcytic anaemia) or with an evidence of iron overload (e.g., haemochromatosis) or disturbances in the utilisation of iron.
  11. Subject has known to any of the study products to be administered or known serious hypersensitivity to other parenteral iron products.
  12. Subject with known severe allergies including drug allergies, history of severe asthma, eczema or other atopic allergy and in subjects with immune or inflammatory conditions (e.g., systemic lupus erythematosus, rheumatoid arthritis).
  13. History of erythropoietin stimulating agent, IV iron therapy, and/or blood transfusion in previous 3 months prior to randomisation.
  14. Oral iron therapy at doses >100 mg/day in previous 4 weeks prior to randomisation. Note: Ongoing use of multivitamins containing iron \<75 mg/day are permitted.
  15. Currently receiving systemic chemotherapy and/or radiotherapy.
  16. Renal dialysis (previous, current or planned within the next 6 months).
  17. Subject has known active of any organ system, i.e., clinical evidence of current malignancy or not in stable remission for at least 3 years since completion of last treatment with exception of non-invasive basal cell carcinoma, squamous cell carcinoma of the skin or cervical intra-epithelial neoplasia.
  18. Terminal illness other than HF with expected survival \<12 months.
  19. Chronic liver disease (including active hepatitis) and/or or aspartate transaminase above 3 times the .
  20. Subjects with known surface antigen positivity and/or virus ribonucleic acid positivity.
  21. Subject previously randomised into this study. Note: Subjects may be rescreened but when rescreened, all tests must fall inside the maximum specified screening windows for each criterion.
  22. Subject is currently enrolled in or has completed any other device or drug study \<30 days prior to screening, or is receiving other investigational agent(s).
  23. Subject is pregnant (e.g., positive human chorionic gonadotropin test) or breast feeding.
  24. If of , subject is not using adequate precautions. Subject must agree to use adequate contraception during the study and for 1 month after the last dose of study treatment. A highly effective method of birth control must be used.
  25. Subject has a history of drug or alcohol abuse within 2 years prior to screening.
  26. Subject has a significant medical condition(s), anticipated need for major surgery during the study, or any other kind of disorder that may be associated with increased risk to the subject, or may interfere with study assessments, outcomes, or the ability to provide written or comply with study procedures, in the Investigator's opinion.

    • Following section in italics is applicable for The Netherlands, Spain and Singapore only (NL, ES and SG only): 'The lower threshold of Hb values is set to 10 g/dL.'
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,132 participants (actual)

Study arms

  • Active comparator
    ferric carboxymaltose

    The first dose of study treatment will be administered for all randomised subjects while the patient is still hospitalised for the Index hospitalisation. The subsequent administrations of study treatment will be done as part of the outpatient clinic visits.

    Drug: ferric carboxymaltose

  • Placebo comparator
    normal saline 0.9%

    The first dose of study treatment will be administered for all randomised subjects on the same day as randomisation.

    Other: Normal saline 0.9%

Interventions

  • FCM will be administered as an undiluted bolus injection. The study treatment dose (mL) to be administered will be determined by the patient's body weight and haemoglobin (Hb) value at the respective visits where study treatment will be administered

    Also known as: Injectafer, Ferinject, Renegy, Iroprem

  • OtherNormal saline 0.9%

    Normal saline will be administered as a bolus injection.

06

What researchers measure

Primary outcomes

  1. HF Hospitalizations and CV Death

    HF = Heart Failure, CV = Cardiovascular. The composite of recurrent HF hospitalizations and CV death up to 52 weeks after randomization Total hospitalisations included first and recurrent events. If a participant was hospitalised for heart failure and died within 24 h from any cardiovascular event, this was counted as one event.

    Time frame: up to 52 weeks after randomization

Secondary outcomes

  1. Recurrent CV Hospitalisations and CV Death

    CV = Cardiovascular The composite of recurrent CV hospitalisations and CV death at 52 weeks after randomisation Total hospitalisations included first and recurrent events. If a participant was hospitalised for a cardiovascular reason and died within 24 h of admission from any cardiovascular event, this was counted as one event.

    Time frame: up to 52 weeks after randomization

  2. HF Hospitalisations

    HF = Heart Failure HF hospitalisations up to 52 weeks after randomisation analysed as recurrent event.

    Time frame: up to 52 weeks after randomisation

  3. CV Mortality

    CV = Cardiovascular CV mortality analysed as time to first event at 52 weeks after randomisation.

    Time frame: at 52 weeks after randomisation.

  4. Composite of HF Hospitalisations or CV Death

    HF = Heart Failure, CV = Cardiovascular Analysed as time to first event at 52 weeks after randomisation. The number of participants with at least one HF Hospitalisation or CV Death is presented below.

    Time frame: at 52 weeks after randomisation

  5. Days Lost Due to HF Hospitalisation or CV Death

    HF = Heart Failure, CV = Cardiovascular Number of days lost due to heart failure hospitalisations or cardiovascular death corresponds to the total number of days in hospital for heart failure from randomisation to last known date. Days lost due to cardiovascular death are added to the number of days lost due to heart failure hospitalisation.

    Time frame: at 52 weeks after randomisation

Other outcomes

  1. HF Hospitalisations

    HF = Heart Failure Number of participants with at least one HF Hospitalisation up to 52 weeks after randomisation

    Time frame: up to 52 weeks after randomisation

  2. CV Hospitalisations

    CV = Cardiovascular Number of participants with at least one CV Hospitalisation up to 52 weeks after randomisation

    Time frame: up to 52 weeks after randomisation

  3. All-cause Mortality

    Number of participants who died up to 52 weeks after randomisation

    Time frame: up to 52 weeks after randomisation

  4. Change From Baseline in NYHA Functional Class

    NYHA = New York Heart Association NYHA functional class was assessed as Class I, II, III, IV or V: Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m). Comfortable only at rest. Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. If a participant was hospitalised at any point during any post-baseline visit and did not have any NYHA assessment for this visit, then Class IV was to be imputed for the visit. Class V - Imputed for participants who died. Lower response categories are better for score NYHA.

    Time frame: at 6, 12, 24 and 52 weeks after randomisation

  5. Change From Baseline in the EQ-5D-5L Questionnaire Indexed Value

    EQ-5D-5L: European Quality of Life-5 Dimensions-5 Levels The EQ 5D questionnaire consists of a health descriptive system for participants to self-classify and rate their health status on the day of administration. The descriptive system includes 5 items/dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which are coded from 1 (best state) to 5 (worst state).

    Time frame: at 6, 24 and 52 weeks after randomisation

  6. KCCQ-12 Repeated-Measures Model for Analysis of Treatment Difference

    KCCQ = Kansas City Cardiomyopathy Questionnaire The KCCQ 12 is a health-related quality of life questionnaire for Heart Failure. It is a 12 item questionnaire that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge and Quality of life. Scores are generated for each domain and scaled from 0 to 100, with 0 denoting the lowest reportable health status and 100 the highest reportable health status.

    Time frame: up to 52 weeks after randomisation

07

Results

Posted Jun 18, 2021

Participant flow

Participant flow — Overall Study
MilestoneFCM (Ferric Carboxymaltose)Placebo (Normal Saline (NaCl 0.9%))
Started567565
Started treatment559551
Completed427437
Not completed140128
Withdrew: Adverse event01
Withdrew: Death9895
Withdrew: Lost to follow-up11
Withdrew: Physician decision01
Withdrew: Protocol violation610
Withdrew: Withdrawal by subject2715
Withdrew: Other85

Outcome measures

PrimaryHF Hospitalizations and CV Death

HF = Heart Failure, CV = Cardiovascular. The composite of recurrent HF hospitalizations and CV death up to 52 weeks after randomization Total hospitalisations included first and recurrent events. If a participant was hospitalised for heart failure and died within 24 h from any cardiovascular event, this was counted as one event.

Time frame:
up to 52 weeks after randomization
Reported as:
Number · Events
HF Hospitalizations and CV Death
EventsFCM (Ferric Carboxymaltose)Placebo (Normal Saline (NaCl 0.9%))
Full Analysis Set (FAS)293372
Covid-19 Sensitivity Analysis274363
Statistical analysis
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Negative binomial model · p = 0.059 · Annualised event rate ratio (rr): 0.79 · 95% CI 0.62 to 1.01Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Negative binomial model · p = 0.024 · Annualised event rate ratio (rr): 0.75 · 95% CI 0.59 to 0.96Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.
SecondaryRecurrent CV Hospitalisations and CV Death

CV = Cardiovascular The composite of recurrent CV hospitalisations and CV death at 52 weeks after randomisation Total hospitalisations included first and recurrent events. If a participant was hospitalised for a cardiovascular reason and died within 24 h of admission from any cardiovascular event, this was counted as one event.

Time frame:
up to 52 weeks after randomization
Reported as:
Number · Events
Recurrent CV Hospitalisations and CV Death
EventsFCM (Ferric Carboxymaltose)Placebo (Normal Saline (NaCl 0.9%))
Full Analysis Set (FAS)370451
COVID-19 sensitivity analyses350440
Statistical analysis
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Negative binomial model · p = 0.050 · Annualised event rate ratio (rr): 0.80 · 95% CI 0.64 to 1.0Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Negative binomial model · p = 0.024 · Annualised event rate ratio (rr): 0.77 · 95% CI 0.62 to 0.97Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.
SecondaryHF Hospitalisations

HF = Heart Failure HF hospitalisations up to 52 weeks after randomisation analysed as recurrent event.

Time frame:
up to 52 weeks after randomisation
Reported as:
Number · Events
HF Hospitalisations
EventsFCM (Ferric Carboxymaltose)Placebo (Normal Saline (NaCl 0.9%))
Full Analysis Set (FAS)217294
COVID-19 sensitivity analyses202287
Statistical analysis
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Negative binomial model · p = 0.013 · Annualised event rate ratio (rr): 0.74 · 95% CI 0.58 to 0.94Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Negative binomial model · p = 0.005 · Annualised event rate ratio (rr): 0.70 · 95% CI 0.55 to 0.90Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.
SecondaryCV Mortality

CV = Cardiovascular CV mortality analysed as time to first event at 52 weeks after randomisation.

Time frame:
at 52 weeks after randomisation.
Reported as:
Count of participants · Participants
CV Mortality
ParticipantsFCM (Ferric Carboxymaltose)Placebo (Normal Saline (NaCl 0.9%))
Full Analysis Set (FAS)7778
COVID-19 sensitivity analyses7376
Statistical analysis
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Regression, Cox · p = 0.809 · Hazard ratio (hr): 0.96 · 95% CI 0.70 to 1.32Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline.
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Regression, Cox · p = 0.687 · Hazard ratio (hr): 0.94 · 95% CI 0.68 to 1.29Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline
SecondaryComposite of HF Hospitalisations or CV Death

HF = Heart Failure, CV = Cardiovascular Analysed as time to first event at 52 weeks after randomisation. The number of participants with at least one HF Hospitalisation or CV Death is presented below.

Time frame:
at 52 weeks after randomisation
Reported as:
Count of participants · Participants
Composite of HF Hospitalisations or CV Death
ParticipantsFCM (Ferric Carboxymaltose)Placebo (Normal Saline (NaCl 0.9%))
Full Analysis Set (FAS)181209
COVID-19 sensitivity analyses175205
Statistical analysis
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Regression, Cox · p = 0.030 · Hazard ratio (hr): 0.80 · 95% CI 0.66 to 0.98Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Regression, Cox · p = 0.023 · Hazard ratio (hr): 0.79 · 95% CI 0.65 to 0.97Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline
SecondaryDays Lost Due to HF Hospitalisation or CV Death

HF = Heart Failure, CV = Cardiovascular Number of days lost due to heart failure hospitalisations or cardiovascular death corresponds to the total number of days in hospital for heart failure from randomisation to last known date. Days lost due to cardiovascular death are added to the number of days lost due to heart failure hospitalisation.

Time frame:
at 52 weeks after randomisation
Reported as:
Mean · days
Days Lost Due to HF Hospitalisation or CV Death
daysFCM (Ferric Carboxymaltose)Placebo (Normal Saline (NaCl 0.9%))
Full Analysis Set (FAS)3.8 ± 9.066.2 ± 14.48
COVID-19 sensitivity analyses3.5 ± 8.186.1 ± 14.42
Statistical analysis
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Negative binomial model · p = 0.035 · Annualised event rate ratio (rr): 0.67 · 95% CI 0.47 to 0.97Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country.
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Negative binomial model · p = 0.009 · Annualised event rate ratio (rr): 0.61 · 95% CI 0.42 to 0.88Negative binomial model adjusted for baseline covariates: sex, age, HF aetiology, HF duration, and country
Other pre-specifiedHF Hospitalisations

HF = Heart Failure Number of participants with at least one HF Hospitalisation up to 52 weeks after randomisation

Time frame:
up to 52 weeks after randomisation
Reported as:
Count of participants · Participants
HF Hospitalisations
ParticipantsFCM (Ferric Carboxymaltose)Placebo (Normal Saline (NaCl 0.9%))
HF Hospitalisations142178
Statistical analysis
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Regression, Cox · p = 0.006 · Hazard ratio (hr): 0.73 · 95% CI 0.59 to 0.92Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline.
Other pre-specifiedCV Hospitalisations

CV = Cardiovascular Number of participants with at least one CV Hospitalisation up to 52 weeks after randomisation

Time frame:
up to 52 weeks after randomisation
Reported as:
Count of participants · Participants
CV Hospitalisations
ParticipantsFCM (Ferric Carboxymaltose)Placebo (Normal Saline (NaCl 0.9%))
CV Hospitalisations181220
Statistical analysis
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Regression, Cox · p = 0.009 · Hazard ratio (hr): 0.77 · 95% CI 0.63 to 0.94Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline.
Other pre-specifiedAll-cause Mortality

Number of participants who died up to 52 weeks after randomisation

Time frame:
up to 52 weeks after randomisation
Reported as:
Count of participants · Participants
All-cause Mortality
ParticipantsFCM (Ferric Carboxymaltose)Placebo (Normal Saline (NaCl 0.9%))
All-cause Mortality9896
Statistical analysis
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Regression, Cox · p = 0.944 · Hazard ratio (hr): 0.99 · 95% CI 0.75 to 1.31Cox regression adjusted for sex, age, HF aetiology, HF duration, and country at baseline
Other pre-specifiedChange From Baseline in NYHA Functional Class

NYHA = New York Heart Association NYHA functional class was assessed as Class I, II, III, IV or V: Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m). Comfortable only at rest. Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. If a participant was hospitalised at any point during any post-baseline visit and did not have any NYHA assessment for this visit, then Class IV was to be imputed for the visit. Class V - Imputed for participants who died. Lower response categories are better for score NYHA.

Time frame:
at 6, 12, 24 and 52 weeks after randomisation
Reported as:
Count of participants · Participants
Change From Baseline in NYHA Functional Class
ParticipantsFCM (Ferric Carboxymaltose)Placebo (Normal Saline (NaCl 0.9%))
Baseline — Class I148
Baseline — Class II255240
Baseline — Class III272277
Baseline — Class IV1622
Baseline — Class V00
Week 6 — Class I3838
Week 6 — Class II296271
Week 6 — Class III151151
Week 6 — Class IV1331
Week 6 — Class V1823
Week 12 — Class I3940
Week 12 — Class II296267
Week 12 — Class III107131
Week 12 — Class IV1418
Week 12 — Class V3632
Week 24 — Class I4747
Week 24 — Class II288265
Week 24 — Class III88100
Week 24 — Class IV1320
Week 24 — Class V5663
Week 52 — Class I4853
Week 52 — Class II234223
Week 52 — Class III6175
Week 52 — Class IV717
Week 52 — Class V9995
Statistical analysis
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Generalised Estimating Equations (GEE) · p = 0.196 · Odds ratio (or): 1.14 · 95% CI 0.93 to 1.39The following variables are included in the GEE model: treatment, visit, baseline NYHA class, sex, age, HF aetiology, HF duration, and country
Other pre-specifiedChange From Baseline in the EQ-5D-5L Questionnaire Indexed Value

EQ-5D-5L: European Quality of Life-5 Dimensions-5 Levels The EQ 5D questionnaire consists of a health descriptive system for participants to self-classify and rate their health status on the day of administration. The descriptive system includes 5 items/dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which are coded from 1 (best state) to 5 (worst state).

Time frame:
at 6, 24 and 52 weeks after randomisation
Reported as:
Mean · Change from baseline in EQ-5D-5L
Change From Baseline in the EQ-5D-5L Questionnaire Indexed Value
Change from baseline in EQ-5D-5LFCM (Ferric Carboxymaltose)Placebo (Normal Saline (NaCl 0.9%))
Week 60.05 ± 0.010.03 ± 0.01
Week 240.06 ± 0.010.05 ± 0.01
Week 520.06 ± 0.010.06 ± 0.01
Statistical analysis
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Mixed-effect model of repeated measures · p = 0.208MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\*Visit + Baseline covariates.
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Mixed-effect model of repeated measures · p = 0.408MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\*Visit + Baseline covariates.
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Mixed-effect model of repeated measures · p = 0.999MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\*Visit + Baseline covariates.
Other pre-specifiedKCCQ-12 Repeated-Measures Model for Analysis of Treatment Difference

KCCQ = Kansas City Cardiomyopathy Questionnaire The KCCQ 12 is a health-related quality of life questionnaire for Heart Failure. It is a 12 item questionnaire that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge and Quality of life. Scores are generated for each domain and scaled from 0 to 100, with 0 denoting the lowest reportable health status and 100 the highest reportable health status.

Time frame:
up to 52 weeks after randomisation
Reported as:
Mean · KCCQ-12 score
KCCQ-12 Repeated-Measures Model for Analysis of Treatment Difference
KCCQ-12 scoreFCM (Ferric Carboxymaltose)Placebo (Normal Saline (NaCl 0.9%))
Week 218.53 ± 1.1617.24 ± 1.19
Week 421.26 ± 1.1818.36 ± 1.21
Week 623.49 ± 1.2019.88 ± 1.23
Week 1225.57 ± 1.2421.88 ± 1.26
Week 2426.30 ± 1.2623.32 ± 1.27
Week 3625.78 ± 1.2823.70 ± 1.30
Week 5225.75 ± 1.3324.31 ± 1.34
Statistical analysis
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Mixed-effect model of repeated measures · p = 0.227MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\*Visit + Baseline covariates.
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Mixed-effect model of repeated measures · p = 0.018MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\*Visit + Baseline covariates.
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Mixed-effect model of repeated measures · p = 0.005MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\*Visit + Baseline covariates.
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Mixed-effect model of repeated measures · p = 0.006MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\*Visit + Baseline covariates.
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Mixed-effect model of repeated measures · p = 0.028MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\*Visit + Baseline covariates.
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Mixed-effect model of repeated measures · p = 0.136MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\*Visit + Baseline covariates.
  • FCM (Ferric Carboxymaltose) vs Placebo (Normal Saline (NaCl 0.9%)) · Mixed-effect model of repeated measures · p = 0.329MMRM using unstructured covariance matrix: Change score = Baseline score + Treatment + Visit + Treatment\*Visit + Baseline covariates.

Adverse events

Collected over During treatment period up to 52 weeks after randomization. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1 - FCM (Ferric Carboxymaltose)99/559 (17.7%)250/559 (44.7%)51/559 (9.1%)
Group 2 - Placebo (Normal Saline (NaCl 0.9%))96/551 (17.4%)282/551 (51.2%)45/551 (8.2%)
Most frequent serious events
Showing 10 of 259
Most frequent serious events
EventGroup 1 - FCM (Ferric Carboxymaltose)Group 2 - Placebo (Normal Saline (NaCl 0.9%))
Cardiac failureCardiac disorders116/559127/551
Cardiac failure congestiveCardiac disorders20/55923/551
Cardiac failure acuteCardiac disorders21/55917/551
PneumoniaInfections and infestations11/55915/551
DeathGeneral disorders8/55913/551
Cardiac arrestCardiac disorders8/55911/551
Atrial fibrillationCardiac disorders10/5594/551
SepsisInfections and infestations7/5599/551
Acute myocardial infarctionCardiac disorders2/5598/551
Pulmonary congestionRespiratory, thoracic and mediastinal disorders1/5598/551
Most frequent other events
Most frequent other events
EventGroup 1 - FCM (Ferric Carboxymaltose)Group 2 - Placebo (Normal Saline (NaCl 0.9%))
Cardiac failureCardiac disorders51/55945/551

Baseline characteristics

Age, Customized
Age, Customized(Participants)FCM (Ferric Carboxymaltose)Placebo (Normal Saline (NaCl 0.9%))Total
<18 years000
Between 18 and 64 years139142281
Between 65 and 84 years369370739
≥ 85 years513990
Sex: Female, Male
Sex: Female, Male(Participants)FCM (Ferric Carboxymaltose)Placebo (Normal Saline (NaCl 0.9%))Total
Female244250494
Male315301616
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FCM (Ferric Carboxymaltose)Placebo (Normal Saline (NaCl 0.9%))Total
Hispanic or Latino5150101
Not Hispanic or Latino498489987
Unknown or Not Reported101222
Region of Enrollment
Region of Enrollment(Participants)FCM (Ferric Carboxymaltose)Placebo (Normal Saline (NaCl 0.9%))Total
Argentina242448
Brazil141428
Croatia394382
Georgia9895193
Israel413879
Italy5558113
Lebanon161632
Netherlands383169
Poland9090180
Romania7678154
Singapore232245
Spain121224
Sweden415
Ukraine232346
United Kingdom6612
08

Study locations

16 sites
  • Hospital Universitario Austral
    Buenos Aires, 1500, Argentina
  • InCor -Instituto do Coração HCFMUSP
    São Paulo, 05403-900, Brazil
  • Clinical Hospital Center Rijeka
    Rijeka, Croatia
  • Aleksandre Aladashvili Clinic LLC
    Tbilisi, 0102, Georgia
  • The Baruch Pade Medical Center
    Tiberias, Lower Galilee 15208, Israel
  • Hadassah Ein Kerem University Medical Center
    Jerusalem, 91120, Israel
  • Spedali Civilia di Brescia
    Brescia, Italy
  • American University of Beirut Medical Center
    Beirut, 1107-2020, Lebanon
  • Vasculair Onderzoek Centrum
    Hoorn, Netherlands
  • Clinical Military Hospital
    Wroclaw, 50-891, Poland
  • Emergency Clinical Hospital
    Bucharest, 014461, Romania
  • National Heart Centre of Singapore Pte
    Singapore, 169609, Singapore
  • University of Murcia
    Murcia, 30001, Spain
  • Skane University Hospital
    Malmö, SE 20502, Sweden
  • The M.D. Strazhesko Institute of Cardiology
    Kyiv, 02000, Ukraine
  • Kings College Hospital NHS Foundation
    London, United Kingdom
09

References and documents

Publications

  • Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Gohring UM, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Butler J, Friede T, Jensen KH, Pocock S, Jankowska EA; AFFIRM-AHF investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020 Dec 12;396(10266):1895-1904. doi: 10.1016/S0140-6736(20)32339-4. Epub 2020 Nov 13. Erratum In: Lancet. 2021 Nov 27;398(10315):1964. doi: 10.1016/S0140-6736(21)02492-2. PubMed 33197395 ↗
  • Ponikowski P, Kirwan BA, Anker SD, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Haboubi T, Keren A, Khintibidze I, Kragten H, Martinez FA, McDonagh T, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Jankowska EA. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. Eur J Heart Fail. 2019 Dec;21(12):1651-1658. doi: 10.1002/ejhf.1710. Epub 2019 Dec 28. PubMed 31883356 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Jul 2020, 39 months.

Results were first posted in Jun 2021, 10 months after primary completion.

Of 26 phase 4 interventional studies under Iron Deficiencies, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's 39 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2016
First posted
Oct 18, 2016
StartActual
Apr 3, 2017
Primary completionActual
Jul 21, 2020
CompletionActual
Jul 21, 2020
Results first posted
Jun 18, 2021
Last update
Jun 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02937454
Collaborators
Worldwide Clinical Trials, Cytel Inc.
Responsible party
Sponsor
First posted
Oct 18, 2016
Start date
Apr 3, 2017
Primary completion
Jul 21, 2020
Completion
Jul 21, 2020
Results posted
Jun 18, 2021
Last update
Jun 18, 2021

Study contacts

Piotr Ponikowski, MD
principal investigator · Medical University Clinical Military Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion